Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, May 2, 2024 -- For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published online May 1 in The Journal of Urology.
Hongyang Qian, from Shanghai Jiao Tong University, and colleagues conducted a randomized trial recruiting 141 patients with locally advanced, high-risk prostate cancer who were randomly assigned to the NCHT group (who received docetaxel plus androgen deprivation therapy for six cycles) or the neoadjuvant hormone therapy (NHT) group (who received androgen deprivation therapy for 24 weeks) in a 2:1 ratio. Three-year bPFS was examined as the primary end point.
The researchers identified significant benefits in three-year bPFS for the NCHT group versus the NHT group (29 versus 9.5 percent). The NCHT group achieved a significantly longer median bPFS time than the NHT group at a median follow-up of 53 months (17 versus 14 months). In terms of pathological downstaging and minimal residual disease rates, there were no significant differences observed between the groups.
"Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced, high-risk prostate cancer," coauthor Jiahua Pan, M.D., also of Shanghai Jiao Tong University, said in a statement. "The findings add new evidence to support the use of combined chemohormonal therapy for a group of patients at high risk of recurrent, progressive prostate cancer."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Black Patients More Likely to Experience MACE After ADT for Prostate Cancer
THURSDAY, June 20, 2024 -- Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy (ADT) for prostate cancer...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.